Primary care screening to identify symptomatic menopausal women

The use of a screening tool in primary care to identify menopausal and perimenopausal women who could benefit from hormone replacement therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13287757

Enrollment

Registered

2021-08-13

Start date

2021-02-06

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary care screening to identify symptomatic menopausal women Nutritional, Metabolic, Endocrine

Interventions

This will be an uncontrolled before and after intervention study with participants recruited from primary care. The intervention consists of the use of the menopause rating scale (MRS) combined with t

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All women between the ages of 47 and 53 years who are currently not prescribed any form of hormone replacement therapy and who have no recorded contra-indications to using the treatment

Exclusion criteria

Exclusion criteria: 1. Current, past or suspected breast cancer 2. Known or suspected oestrogen-sensitive cancer 3. Undiagnosed vaginal bleeding 4. Untreated endometrial hyperplasia 5. Previous idiopathic or current deep vein thrombosis or pulmonary embolism unless on anticoagulant therapy. 6. Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction) 7. Untreated hypertension 8. Active liver disease with abnormal liver function tests 9. Porphyria cutanea tarda 10. Pregnancy

Design outcomes

Primary

Measure	Time frame
Menopause symptom severity measures using the MRS and MenQol scales at 3 months	—

Secondary

Measure	Time frame
Uptake of HRT measured using self report at 3 months	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026